Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGAV | P06756 | 2/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346962 | 0.92 | ITGB1 (0.47) | ITGB1ITGA5ITGB3ITGAVGPR139 | |
| SCHEMBL7338985 | 0.85 | ITGB3 (0.47) | ITGB1ITGA5KMT2AITGB3ITGAV | |
| SCHEMBL7350678 | 0.85 | ITGB1 (0.53) | ITGB1ITGA5ITGB3ITGAVGPR139 | |
| SCHEMBL6774128 | 0.84 | GPR139 (0.44) | ITGB1ITGA5MEN1KMT2AITGB3 | |
| SCHEMBL6774132 | 0.84 | GPR139 (0.44) | ITGB1ITGA5MEN1KMT2AITGB3 | |
| SCHEMBL6773783 | 0.82 | NAMPT (0.52) | TP53ITGB3ITGAVALDH1A1MAPT | |
| SCHEMBL6778759 | 0.82 | TP53 (0.48) | TP53MEN1KMT2ANOD2GPR139 | |
| SCHEMBL6783596 | 0.81 | ACE (0.47) | ITGB1ITGA5MEN1KMT2AITGB3 | |
| SCHEMBL7338413 | 0.81 | TP53 (0.42) | TP53MEN1KMT2ANOD2GPR139 | |
| SCHEMBL7344520 | 0.81 | CTSV (0.40) | TP53ITGB1ITGA5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |